John Todd Arnedt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John Todd Arnedt has a total of 431 co-authors. Here are the top co-authors by number of shared publications:
- Deirdre A. Conroy
A Department of Psychiatry , University of Michigan , Ann Arbor , Michigan
12 shared publications Roseanne Armitage
University of Michigan, Ann Arbor, MI, United States
11 shared publicationsDeirdre A. Conroy
Sleep and Circadian Research Laboratory, Department of Psychiatry, Michigan Medicine, University of Michigan, 4250 Plymouth Road, Ann Arbor, MI 48109, USA
10 shared publications- Kirk J. Brower
Department of Psychiatry, University of Michigan Medical School, Ann Arbor, Michigan, USA
9 shared publications Richard P. Millman
Departments of Medicine and Pediatrics, Alpert Medical School of Brown University, Providence, RI
8 shared publications- Christopher Lawrence Drake
Department of Medicine, College of Human Medicine, Michigan State University, East Lansing, USA
7 shared publications
Latest Publications
- Open Access
Cognitive-behavioural therapy for insomnia in adults to decrease cannabis use: study protocol for a randomised controlled trial in a community sample of adults with frequent cannabis use
Introduction Cannabis use is common in the USA and is associated with adverse outcomes across many domains, including sleep difficulties. Targeting insomnia with an evidence-based treatment could improve sleep and reduce frequent cannabis use. This randomised controlled trial (RCT) will compare evidence-based telemedicine-delivered cognitive-behavioural therapy for insomnia for adults with frequent cannabis use (CBTi-CB) against an active comparator, sleep hygiene education (SHE), for improving insomnia/sleep, associated daytime symptoms and cannabis use. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes. Methods and analysis This is a single-site RCT with planned enrolment of 200 adults (21+ years of age) who meet criteria for both chronic insomnia and frequent cannabis use. Eligible participants will be randomised 1:1 to six sessions of CBTi-CB or SHE with clinical assessments conducted at pre-treatment, post-treatment and at 3 and 6 months post-treatment. Overnight polysomnography (PSG) will be conducted before and after treatment. Primary outcomes will include the Insomnia Severity Index, 12-item Short-Form Health Survey Mental Composite Score and cannabis use frequency as assessed by the interview-administered Timeline Follow Back. Electroencephalogram delta activity, derived from overnight PSG, will be the primary end point to assess the sleep homeostasis mechanism. Ethics and dissemination Ethical approval for the study has been obtained from the Institutional Review Board of the University of Michigan Medical School (IRBMED #HUM00222302). The results of the investigation will be published in scientific papers. The data from the investigation will be made available through the National Institutes of Health (NIH) National Data Archive, which allows researchers on NIH grants to share and access raw data. Trial registration number NCT05814822.
Open AccessCognitive-behavioural therapy for insomnia in adults to decrease cannabis use: study protocol for a randomised controlled trial in a community sample of adults with frequent cannabis use
Introduction Cannabis use is common in the USA and is associated with adverse outcomes across many domains, including sleep difficulties. Targeting insomnia with an evidence-based treatment could improve sleep and reduce frequent cannabis use. This randomised controlled trial (RCT) will compare evidence-based telemedicine-delivered cognitive-behavioural therapy for insomnia for adults with frequent cannabis use (CBTi-CB) against an active comparator, sleep hygiene education (SHE), for improving insomnia/sleep, associated daytime symptoms and cannabis use. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes. Methods and analysis This is a single-site RCT with planned enrolment of 200 adults (21+ years of age) who meet criteria for both chronic insomnia and frequent cannabis use. Eligible participants will be randomised 1:1 to six sessions of CBTi-CB or SHE with clinical assessments conducted at pre-treatment, post-treatment and at 3 and 6 months post-treatment. Overnight polysomnography (PSG) will be conducted before and after treatment. Primary outcomes will include the Insomnia Severity Index, 12-item Short-Form Health Survey Mental Composite Score and cannabis use frequency as assessed by the interview-administered Timeline Follow Back. Electroencephalogram delta activity, derived from overnight PSG, will be the primary end point to assess the sleep homeostasis mechanism. Ethics and dissemination Ethical approval for the study has been obtained from the Institutional Review Board of the University of Michigan Medical School (IRBMED #HUM00222302). The results of the investigation will be published in scientific papers. The data from the investigation will be made available through the National Institutes of Health (NIH) National Data Archive, which allows researchers on NIH grants to share and access raw data. Trial registration number NCT05814822.
- Open Access
- 15 April 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 58
Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
Introduction This systematic review provides supporting evidence for the accompanying clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Methods The American Academy of Sleep Medicine (AASM) commissioned a task force (TF) of sleep medicine experts. A systematic review was conducted to identify studies that compared the use of combination treatment (behavioral-psychological treatment used concurrently with pharmacological treatment) to therapy with behavioral-psychological or pharmacological treatments. Statistical analyses were performed to determine the clinical meaningfulness of using various interventions to treat chronic insomnia in adults. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence for making recommendations. Results The literature search resulted in 1,179 articles, out of which 15 articles provided data suitable for meta-analyses. The TF provided a detailed summary of the evidence along with the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations.
- 15 April 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1) , 58
Open AccessCombination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
Introduction This systematic review provides supporting evidence for the accompanying clinical practice guideline on combination treatment for chronic insomnia disorder in adults. Methods The American Academy of Sleep Medicine (AASM) commissioned a task force (TF) of sleep medicine experts. A systematic review was conducted to identify studies that compared the use of combination treatment (behavioral-psychological treatment used concurrently with pharmacological treatment) to therapy with behavioral-psychological or pharmacological treatments. Statistical analyses were performed to determine the clinical meaningfulness of using various interventions to treat chronic insomnia in adults. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process was used to assess the evidence for making recommendations. Results The literature search resulted in 1,179 articles, out of which 15 articles provided data suitable for meta-analyses. The TF provided a detailed summary of the evidence along with the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations.
- Top Cited PapersOpen Access
- 13 April 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1)
Combination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline
This guideline establishes clinical practice recommendations for combination treatment of chronic insomnia disorder in adults, defined here as treatment with cognitive-behavioral therapy for insomnia (CBT-I) started concurrently with pharmacotherapy. The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths to those recommendations based on a systematic review of the literature and an assessment of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process. The task force provided a summary of the relevant literature, the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations. The following recommendations are intended as a guide for clinicians on the use of combination treatment for chronic insomnia disorder in adults. Each recommendation statement is assigned a strength (“Strong” or “Conditional”). A “Strong” recommendation (i.e., “We recommend…”) is one that clinicians should follow under most circumstances. A “Conditional” recommendation (i.e., “We suggest…”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the patient’s values and preferences to determine the best course of action. One recommendation includes a remark that provides additional context to guide clinicians with implementation of this recommendation. Conditional recommendation for: 1. In adults with chronic insomnia disorder, the AASM suggests the use of combination treatment with CBT-I plus insomnia medication over insomnia medication alone. (Conditional recommendation, low certainty of evidence). Conditional recommendation against: 2. In adults with chronic insomnia disorder, the AASM suggests against the use of combination treatment of CBT-I plus insomnia medication over CBT-I alone. (Conditional recommendation, low certainty of evidence). Remark: Patients who place higher value on increasing total sleep time early in the course of treatment, and/or who place lower value on reducing daytime symptoms with treatment, may reasonably select combination treatment versus CBT-I alone.
- 13 April 2026
- Published by Springer Nature in Journal of Clinical Sleep Medicine
- Vol. 22 (1)
Top Cited PapersOpen AccessCombination treatment for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline
This guideline establishes clinical practice recommendations for combination treatment of chronic insomnia disorder in adults, defined here as treatment with cognitive-behavioral therapy for insomnia (CBT-I) started concurrently with pharmacotherapy. The American Academy of Sleep Medicine (AASM) commissioned a task force of experts in sleep medicine to develop recommendations and assign strengths to those recommendations based on a systematic review of the literature and an assessment of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) process. The task force provided a summary of the relevant literature, the certainty of evidence, the balance of benefits and harms, patient values and preferences, and resource use considerations that support the recommendations. The AASM Board of Directors approved the final recommendations. The following recommendations are intended as a guide for clinicians on the use of combination treatment for chronic insomnia disorder in adults. Each recommendation statement is assigned a strength (“Strong” or “Conditional”). A “Strong” recommendation (i.e., “We recommend…”) is one that clinicians should follow under most circumstances. A “Conditional” recommendation (i.e., “We suggest…”) is one that requires that the clinician use clinical knowledge and experience and strongly consider the patient’s values and preferences to determine the best course of action. One recommendation includes a remark that provides additional context to guide clinicians with implementation of this recommendation. Conditional recommendation for: 1. In adults with chronic insomnia disorder, the AASM suggests the use of combination treatment with CBT-I plus insomnia medication over insomnia medication alone. (Conditional recommendation, low certainty of evidence). Conditional recommendation against: 2. In adults with chronic insomnia disorder, the AASM suggests against the use of combination treatment of CBT-I plus insomnia medication over CBT-I alone. (Conditional recommendation, low certainty of evidence). Remark: Patients who place higher value on increasing total sleep time early in the course of treatment, and/or who place lower value on reducing daytime symptoms with treatment, may reasonably select combination treatment versus CBT-I alone.
- Open Access
- 8 January 2026
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 7 (1)
Cognitive behavioral therapy for insomnia modified for adults with hazardous alcohol use: an open-label pilot study
Study Objectives: Insomnia is highly prevalent and frequently comorbid with alcohol misuse. Cognitive behavioral therapy for insomnia (CBTi), the first line treatment for chronic insomnia, improves insomnia in adults with alcohol use disorder but has seldom been evaluated in at-risk populations, such as individuals with hazardous alcohol use (HAU). In an open-label pilot trial, we tested the feasibility and acceptability of a modified CBTi to simultaneously address insomnia and co-occurring HAU (CBTi-HAU). Methods: Ten community-dwelling participants 25–64 years of age with HAU and chronic insomnia disorder engaged in four CBTi-HAU sessions via phone or Zoom with a trained therapist and completed pre- and post-treatment assessments of sleep, alcohol use, and daytime symptoms. Results: All participants completed the intervention with 9/10 completing the post-treatment assessment. Patient feedback about the treatment was largely positive and supported acceptability. The pre-post-reduction of 10.7 points on the insomnia severity index (p < .001; 95% CI: 8.53; 12.8) represents a large effect (g = 3.46; 95% CI: 1.69; 5.21) that is clinically meaningful. Participants additionally reported statistically significant reductions in percent heavy drinking days and alcohol-related problems with moderate to large effects, but not days abstinent or drinks per drinking day. Conclusions: CBTi-HAU is a promising and feasible intervention for improving insomnia symptoms and reducing problematic drinking behaviors in an at-risk population. These preliminary findings require replication in a randomized clinical trial.
- 8 January 2026
- Published by Oxford University Press (OUP) in SLEEP Advances
- Vol. 7 (1)
Open AccessCognitive behavioral therapy for insomnia modified for adults with hazardous alcohol use: an open-label pilot study
Study Objectives: Insomnia is highly prevalent and frequently comorbid with alcohol misuse. Cognitive behavioral therapy for insomnia (CBTi), the first line treatment for chronic insomnia, improves insomnia in adults with alcohol use disorder but has seldom been evaluated in at-risk populations, such as individuals with hazardous alcohol use (HAU). In an open-label pilot trial, we tested the feasibility and acceptability of a modified CBTi to simultaneously address insomnia and co-occurring HAU (CBTi-HAU). Methods: Ten community-dwelling participants 25–64 years of age with HAU and chronic insomnia disorder engaged in four CBTi-HAU sessions via phone or Zoom with a trained therapist and completed pre- and post-treatment assessments of sleep, alcohol use, and daytime symptoms. Results: All participants completed the intervention with 9/10 completing the post-treatment assessment. Patient feedback about the treatment was largely positive and supported acceptability. The pre-post-reduction of 10.7 points on the insomnia severity index (p < .001; 95% CI: 8.53; 12.8) represents a large effect (g = 3.46; 95% CI: 1.69; 5.21) that is clinically meaningful. Participants additionally reported statistically significant reductions in percent heavy drinking days and alcohol-related problems with moderate to large effects, but not days abstinent or drinks per drinking day. Conclusions: CBTi-HAU is a promising and feasible intervention for improving insomnia symptoms and reducing problematic drinking behaviors in an at-risk population. These preliminary findings require replication in a randomized clinical trial.
- 25 February 2025
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 27 (4) , 199-205
Sleep and Substance Use: Exploring Reciprocal Impacts and Therapeutic Approaches
Purpose of Review Sleep disturbances are prevalent among those with comorbid substance use disorders (SUD), significantly impacting the initiation, maintenance and relapse of these conditions. Recent Findings This review explores the latest research on the reciprocal relationship between sleep and substance misuse, the effects of treating sleep on substance use outcomes, and the potential therapeutic uses of cannabis for sleep disorders in people with and without SUDs. Summary Understanding these interactions may be critical for augmenting current treatment strategies aimed at improving sleep disturbances and recovery outcomes in individuals with SUDs.
- 25 February 2025
- Published by Springer Nature in Current Psychiatry Reports
- Vol. 27 (4) , 199-205
Sleep and Substance Use: Exploring Reciprocal Impacts and Therapeutic Approaches
Purpose of Review Sleep disturbances are prevalent among those with comorbid substance use disorders (SUD), significantly impacting the initiation, maintenance and relapse of these conditions. Recent Findings This review explores the latest research on the reciprocal relationship between sleep and substance misuse, the effects of treating sleep on substance use outcomes, and the potential therapeutic uses of cannabis for sleep disorders in people with and without SUDs. Summary Understanding these interactions may be critical for augmenting current treatment strategies aimed at improving sleep disturbances and recovery outcomes in individuals with SUDs.
- 11 March 2023
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 246, 109835
Cognitive behavioral therapy for insomnia to reduce cannabis use: Results from a pilot randomized controlled trial
- 11 March 2023
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 246, 109835
Cognitive behavioral therapy for insomnia to reduce cannabis use: Results from a pilot randomized controlled trial
- Open Access
- 20 January 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-14
Telemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial
Background: Alcohol use disorder (AUD) is a leading preventable cause of morbidity and mortality, but relapse rates are high even with available treatments. Insomnia is a robust predictor of relapse and pilot studies have shown that CBT for insomnia improves insomnia and daytime functioning in adults with AUD and insomnia. The impact of CBT for insomnia on relapse, however, is unclear. This trial will compare telemedicine-delivered CBT for insomnia (CBT-TM) with sleep hygiene education (SHE-TM) on improving insomnia/sleep, daytime symptom, and drinking outcomes in treatment-seeking AUD adults with insomnia. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes.Methods: This is a single-site randomized controlled trial with planned enrollment of 150 adults meeting criteria for both AUD and chronic insomnia. Eligible participants will be randomized 1:1 to 6 sessions of telemedicine-delivered Cognitive Behavioral Therapy for Insomnia (CBT-TM) or Sleep Hygiene Education (SHE-TM) with clinical assessments conducted at pre-treatment, post- treatment, and at 3, 6, and 12 months post-treatment. Overnight polysomnography will be conducted before and after treatment. Primary clinical outcomes will include post-treatment scores on the Insomnia Severity Index and the General Fatigue subscale of the Multidisciplinary Fatigue Inventory, and the percent of days abstinent (PDA) on the interview-administered Time Line Follow Back. EEG delta activity, derived from overnight polysomnography, will be the primary endpoint to assess the sleep homeostasis mechanism.Discussion: This adequately powered randomized controlled trial will provide clinically relevant information about whether targeting insomnia is effective for improving treatment outcomes among treatment-seeking adults with AUD. Additionally, the study will offer new scientific insights on the impact of an evidence-based non-medication treatment for insomnia on a candidate mechanism of sleep dysfunction in this population - sleep homeostasis.Trial registration: CClinicalTrials.govNCT # 04457674. Registered on 07 July 2020.
- 20 January 2022
- Published by Springer Nature in Trials
- Vol. 23 (1) , 1-14
Open AccessTelemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial
Background: Alcohol use disorder (AUD) is a leading preventable cause of morbidity and mortality, but relapse rates are high even with available treatments. Insomnia is a robust predictor of relapse and pilot studies have shown that CBT for insomnia improves insomnia and daytime functioning in adults with AUD and insomnia. The impact of CBT for insomnia on relapse, however, is unclear. This trial will compare telemedicine-delivered CBT for insomnia (CBT-TM) with sleep hygiene education (SHE-TM) on improving insomnia/sleep, daytime symptom, and drinking outcomes in treatment-seeking AUD adults with insomnia. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes.Methods: This is a single-site randomized controlled trial with planned enrollment of 150 adults meeting criteria for both AUD and chronic insomnia. Eligible participants will be randomized 1:1 to 6 sessions of telemedicine-delivered Cognitive Behavioral Therapy for Insomnia (CBT-TM) or Sleep Hygiene Education (SHE-TM) with clinical assessments conducted at pre-treatment, post- treatment, and at 3, 6, and 12 months post-treatment. Overnight polysomnography will be conducted before and after treatment. Primary clinical outcomes will include post-treatment scores on the Insomnia Severity Index and the General Fatigue subscale of the Multidisciplinary Fatigue Inventory, and the percent of days abstinent (PDA) on the interview-administered Time Line Follow Back. EEG delta activity, derived from overnight polysomnography, will be the primary endpoint to assess the sleep homeostasis mechanism.Discussion: This adequately powered randomized controlled trial will provide clinically relevant information about whether targeting insomnia is effective for improving treatment outcomes among treatment-seeking adults with AUD. Additionally, the study will offer new scientific insights on the impact of an evidence-based non-medication treatment for insomnia on a candidate mechanism of sleep dysfunction in this population - sleep homeostasis.Trial registration: CClinicalTrials.govNCT # 04457674. Registered on 07 July 2020.
- Open Access
- 1 August 2021
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 35, 100814
A preliminary study on the relationship between sleep, depression and cardiovascular dysfunction in a 4 sample population
- 1 August 2021
- Published by Elsevier in IJC Heart & Vasculature
- Vol. 35, 100814
Open AccessA preliminary study on the relationship between sleep, depression and cardiovascular dysfunction in a 4 sample population
- Open Access
- 28 April 2021
- Published by Springer Nature in Research Square
Telemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial
Background: Alcohol use disorder (AUD) is a leading preventable cause of morbidity and mortality, but relapse rates are high even with available treatments. Insomnia is a robust predictor of relapse and pilot studies have shown that CBT for insomnia improves insomnia and daytime functioning in adults with AUD and insomnia. The impact of CBT for insomnia on relapse, however, is unclear. This trial will compare telemedicine-delivered CBT for insomnia (CBT-TM) with sleep hygiene education (SHE-TM) on improving insomnia/sleep, daytime symptom, and drinking outcomes in treatment-seeking AUD adults with insomnia. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes. Methods: This is a single-site randomized controlled trial with planned enrollment of 150 adults meeting criteria for both AUD and chronic insomnia. Eligible participants will be randomized 1:1 to 6 weeks of telemedicine-delivered Cognitive Behavioral Therapy for Insomnia (CBT-TM) or Sleep Hygiene Education (SHE-TM) with clinical assessments conducted at pre-treatment, post- treatment, and at 3-, 6-, and 12-months post-treatment. Overnight polysomnography will be conducted before and after treatment. Primary clinical outcomes will include post-treatment scores on the Insomnia Severity Index and the General Fatigue subscale of the Multidisciplinary Fatigue Inventory, and the percent of days abstinent (PDA) on the interview-administered Time Line Follow Back. EEG delta activity, derived from overnight polysomnography, will be the primary endpoint to assess the sleep homeostasis mechanism. Discussion: This adequately powered randomized controlled trial will provide clinically-relevant information about whether targeting insomnia is effective for improving treatment outcomes among treatment-seeking adults with AUD. Additionally, the study will offer new scientific insights on the impact of an evidence-based non-medication treatment for insomnia on a candidate mechanism of sleep dysfunction in this population - sleep homeostasis.Registration: NCT, NCT # 04457674. Registered 07 July 2020, https://clinicaltrials.gov/ct2/show/NCT04457674?cond=alcohol+use&cntry=US&state=US%3AMI&draw=2&rank=1
- 28 April 2021
- Published by Springer Nature in Research Square
Open AccessTelemedicine-delivered cognitive-behavioral therapy for insomnia in alcohol use disorder (AUD): study protocol for a randomized controlled trial
Background: Alcohol use disorder (AUD) is a leading preventable cause of morbidity and mortality, but relapse rates are high even with available treatments. Insomnia is a robust predictor of relapse and pilot studies have shown that CBT for insomnia improves insomnia and daytime functioning in adults with AUD and insomnia. The impact of CBT for insomnia on relapse, however, is unclear. This trial will compare telemedicine-delivered CBT for insomnia (CBT-TM) with sleep hygiene education (SHE-TM) on improving insomnia/sleep, daytime symptom, and drinking outcomes in treatment-seeking AUD adults with insomnia. The study will also determine the effects of treatment on sleep mechanisms and their association with clinical outcomes. Methods: This is a single-site randomized controlled trial with planned enrollment of 150 adults meeting criteria for both AUD and chronic insomnia. Eligible participants will be randomized 1:1 to 6 weeks of telemedicine-delivered Cognitive Behavioral Therapy for Insomnia (CBT-TM) or Sleep Hygiene Education (SHE-TM) with clinical assessments conducted at pre-treatment, post- treatment, and at 3-, 6-, and 12-months post-treatment. Overnight polysomnography will be conducted before and after treatment. Primary clinical outcomes will include post-treatment scores on the Insomnia Severity Index and the General Fatigue subscale of the Multidisciplinary Fatigue Inventory, and the percent of days abstinent (PDA) on the interview-administered Time Line Follow Back. EEG delta activity, derived from overnight polysomnography, will be the primary endpoint to assess the sleep homeostasis mechanism. Discussion: This adequately powered randomized controlled trial will provide clinically-relevant information about whether targeting insomnia is effective for improving treatment outcomes among treatment-seeking adults with AUD. Additionally, the study will offer new scientific insights on the impact of an evidence-based non-medication treatment for insomnia on a candidate mechanism of sleep dysfunction in this population - sleep homeostasis.Registration: NCT, NCT # 04457674. Registered 07 July 2020, https://clinicaltrials.gov/ct2/show/NCT04457674?cond=alcohol+use&cntry=US&state=US%3AMI&draw=2&rank=1
- 13 July 2020
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 44 (1)
Telemedicine versus face-to-face delivery of cognitive behavioral therapy for insomnia: a randomized controlled noninferiority trial
Study Objectives: In a randomized controlled noninferiority trial, we compared face-to-face and telemedicine delivery (via the AASM SleepTM platform) of cognitive-behavioral therapy (CBT) for insomnia for improving insomnia/sleep and daytime functioning at posttreatment and 3-month follow-up. A secondary objective compared the modalities on treatment credibility, satisfaction, and therapeutic alliance. Methods: A total of 65 adults with chronic insomnia (46 women, 47.2 ± 16.3 years of age) were randomized to 6 sessions of CBT for insomnia delivered individually via AASM SleepTM (n = 33, CBT-TM) or face-to-face (n = 32, CBT-F2F). Participants completed sleep diaries, the Insomnia Severity Index (ISI), and daytime functioning measures at pretreatment, posttreatment, and 3-month follow-up. Treatment credibility, satisfaction, and therapeutic alliance were compared between treatment modalities. The ISI was the primary noninferiority outcome. Results: Based on a noninferiority margin of four points on the ISI and, after adjusting for confounders, CBT-TM was noninferior to CBT-F2F at posttreatment (β = 0.54, SE = 1.10, 95% CI = 1.64 to 2.72) and follow-up (β = 0.34, SE = 1.10, 95% CI = 1.83 to 2.53). Daytime functioning measures, except the physical composite scale of the SF-12, were significantly improved at posttreatment and follow-up, with no difference between treatment formats. CBT-TM sessions were, on average, nearly 10 min shorter, yet participant ratings of therapeutic alliance were similar to CBT-F2F. Conclusions: Telemedicine delivery of CBT for insomnia is not inferior to face-to-face for insomnia severity and yields similar improvements on other sleep and daytime functioning outcomes. Further, telemedicine allows for more efficient treatment delivery while not compromising therapeutic alliance. Clinical Trial Registration Number: NCT03293745
- 13 July 2020
- Published by Oxford University Press (OUP) in SLEEP
- Vol. 44 (1)
Telemedicine versus face-to-face delivery of cognitive behavioral therapy for insomnia: a randomized controlled noninferiority trial
Study Objectives: In a randomized controlled noninferiority trial, we compared face-to-face and telemedicine delivery (via the AASM SleepTM platform) of cognitive-behavioral therapy (CBT) for insomnia for improving insomnia/sleep and daytime functioning at posttreatment and 3-month follow-up. A secondary objective compared the modalities on treatment credibility, satisfaction, and therapeutic alliance. Methods: A total of 65 adults with chronic insomnia (46 women, 47.2 ± 16.3 years of age) were randomized to 6 sessions of CBT for insomnia delivered individually via AASM SleepTM (n = 33, CBT-TM) or face-to-face (n = 32, CBT-F2F). Participants completed sleep diaries, the Insomnia Severity Index (ISI), and daytime functioning measures at pretreatment, posttreatment, and 3-month follow-up. Treatment credibility, satisfaction, and therapeutic alliance were compared between treatment modalities. The ISI was the primary noninferiority outcome. Results: Based on a noninferiority margin of four points on the ISI and, after adjusting for confounders, CBT-TM was noninferior to CBT-F2F at posttreatment (β = 0.54, SE = 1.10, 95% CI = 1.64 to 2.72) and follow-up (β = 0.34, SE = 1.10, 95% CI = 1.83 to 2.53). Daytime functioning measures, except the physical composite scale of the SF-12, were significantly improved at posttreatment and follow-up, with no difference between treatment formats. CBT-TM sessions were, on average, nearly 10 min shorter, yet participant ratings of therapeutic alliance were similar to CBT-F2F. Conclusions: Telemedicine delivery of CBT for insomnia is not inferior to face-to-face for insomnia severity and yields similar improvements on other sleep and daytime functioning outcomes. Further, telemedicine allows for more efficient treatment delivery while not compromising therapeutic alliance. Clinical Trial Registration Number: NCT03293745